Delving into the Latest Updates on Cetuximab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-EGFR monoclonal antibody 225, Cetuximab (Genetical Recombination), Cetuximab (genetical recombination) (JAN)

+ [16]

Target

EGFR

Action

antagonists

Mechanism

EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [5]

Active Indication

BRAF V600E mutant Colorectal CancerRAS Wild Type Colorectal CancerHead and Neck Neoplasms+ [39]

Inactive Indication

Adenocarcinoma of EsophagusAdenocarcinoma of LungAdenocarcinoma of prostate+ [103]

Originator Organization

Merck Serono SA

Active Organization

Pfizer Inc.Merck Sharp & Dohme LLC

Boehringer Ingelheim GmbH

+ [17]

Inactive Organization

Hoffmann-La Roche, Inc.

Novartis AGMerck GmbH

+ [10]

License Organization

Merck KGaA

Eli Lilly & Co.

Genfleet Therapeutics (Shanghai), Inc.

+ [10]

Drug Highest PhaseApproved

First Approval Date

Switzerland (01 Dec 2003),

Colorectal Cancer

RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 43254L

Source: *****

Sequence Code 9505399H

Source: *****

The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who will benefit from the addition of anti-EGFR therapy to first-line chemotherapy.

Start Date15 Apr 2026

Sponsor / Collaborator

Gruppo Oncologico del Nord-Ovest

[+1]

NCT07286149

/ Not yet recruitingPhase 1/2

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn:
* About the safety of MK-1084 and if people tolerate it when taken with other treatments
* How many people have the cancer respond (get smaller or go away) to the treatments

Start Date23 Feb 2026

Sponsor / Collaborator

Merck Sharp & Dohme LLC

[+1]

100 Clinical Results associated with Cetuximab

Login to view more data

100 Translational Medicine associated with Cetuximab

Login to view more data

100 Patents (Medical) associated with Cetuximab

Login to view more data

6,695

Literatures (Medical) associated with Cetuximab

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Non-Coding RNAs and cernas: emerging modulators of drug response in colorectal cancer

Review

Author: Abkenar, Elahe Daskar ; Sadeghi, Amir ; Mojarad, Ehsan Nazemalhosseini ; Nobili, Stefania ; Shams, Elahe ; Moghani, Mona Malekzadeh ; Sina, Negin ; Ebrahimi, Sara ; Fatemi, Nayeralsadat

Colorectal cancer (CRC) is still one of the most common cancers and a leading cause of cancer morbidity worldwide. A significant issue that should be paid much attention to is its resistance to anticancer agents. Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have been identified as important regulators of drug response and drug resistance in CRC. In this review, we provide a comprehensive assessment of the studies conducted in the field of investigating the role of ncRNAs in drug resistance to prominent anticancer agents used in CRC, including 5-fluorouracil (5-FU), oxaliplatin, cetuximab, bevacizumab, and regorafenib. We focussed specifically on the miRNAs, lncRNAs, and circRNAs associated with resistance to each drug individually, even within the context of combination therapies, such as FOLFOX. We also reviewed competing endogenous RNA (ceRNAs) networks and their relationship with drug sensitivity and resistance and new therapeutic strategies to manage drug resistance in CRC and also analyzed the role of ceRNA networks in modulating drug response and its implications for new approaches to overcome drug resistance in CRC. This article also discusses findings from human clinical trials, highlighting evidence from patient studies that validate the role of targeting ceRNA and ncRNA networks in improving drug sensitivity, overcoming resistance, and enhancing therapeutic outcomes in CRC. It supports the targeting of ncRNA and ceRNA networks as potential therapies to improve treatment outcomes and drug resistance in CRC.

01 Mar 2026·Actas Dermo-Sifiliograficas

Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer

Article

Author: Ferreirinha, A ; Moura, C ; Garrido, P M

01 Mar 2026·FREE RADICAL BIOLOGY AND MEDICINE

Redox-driven FABP1/PPARγ signaling fuels peroxisomal fatty acid oxidation and confers cetuximab resistance in drug-tolerant head and neck cancer cells

Article

Author: Kuo, Kuang-Tai ; Ling, Hang Huong ; Hsieh, Ming-Shou ; Yeh, Chi-Tai ; Yadav, Vijesh Kumar ; Tsai, Jo-Ting ; Huang, Chin-Sheng ; Fong, Iat-Hang

Cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is increasingly recognized as an adaptive state driven by metabolic and redox reprogramming that enables tumor cells to tolerate sustained oxidative and immune stress. Although lipid metabolism and PPARγ signaling have been implicated in therapeutic resistance, their functional contribution to drug-tolerant persister (DTP) cells and the role of peroxisomal fatty acid oxidation (FAO) remain poorly defined. In this study, we demonstrate that a redox-driven FABP1/PPARγ axis sustains peroxisome-centered FAO, GPX4-dependent antioxidant defense, and immune suppression in cetuximab-tolerant HNSCC. FABP1 expression was markedly elevated in cetuximab-tolerant DTP cell models and resistant patient tumors. Genetic silencing or pharmacological inhibition of FABP1 using a selective small-molecule inhibitor impaired tumorsphere formation, increased intracellular reactive oxygen species accumulation, and induced apoptotic cell death, accompanied by coordinated suppression of FAO-associated genes, including CPT1, ACSL family members, and acyl-CoA oxidase 1. In an orthotopic SCC9-DTP xenograft model established in NOD-SCID mice, FABP1 inhibition significantly attenuated tumor growth, disrupted metabolic-redox adaptation, and reduced tumor-associated macrophage polarization toward an immunosuppressive phenotype. Our findings identify the FABP1/PPARγ axis as a central regulator of peroxisome-centered FAO and redox buffering in cetuximab-tolerant DTP cells. Targeting FABP1 collapses this adaptive metabolic-redox program, restores vulnerability to oxidative stress, and alleviates immune suppression, highlighting peroxisomal lipid metabolism as a therapeutically actionable vulnerability in refractory HNSCC.

615

News (Medical) associated with Cetuximab

22 Jan 2026

·www.businesswire.com

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling. The accelerated approval was supported by data from Pfizer’s Phase 3 BREAKWATER trial, which evaluated encorafenib-based regimens in previously untreated patients with BRAF-mutated metastatic colorectal cancer mCRC. The study showed that treatment with encorafenib and cetuximab plus mFOLFOX6 chemotherapy significantly improved objective response rate, progression-free and overall survival compared with standard care, underscoring the importance of early genomic testing to guide targeted therapy. Guardant360 CDx expands access to non-invasive genomic testing for this high-risk patient population. Using a simple blood draw to detect BRAF V600E and other clinically relevant genetic alterations, the test helps clinicians quickly identify patients eligible for FDA-approved treatments, enabling timely treatment decisions when tumor tissue is unavailable, insufficient, or when rapid initiation of therapy is clinically necessary. “This latest approval highlights the growing impact of liquid biopsy across advanced cancer care and underscores the utility of Guardant360 CDx in enabling precision therapy selection for patients with diverse, hard-to-treat tumors including aggressive colorectal cancer,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “With multiple FDA-cleared companion diagnostic claims across lung and breast cancer, and now colorectal cancer, and the ability to comprehensively profile tumor genomics from a simple blood draw, Guardant360 CDx is helping clinicians match patients to the right targeted therapies faster and more effectively.” Key highlights of the BREAKWATER trial include: Demonstrated significant improvement in overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) for patients treated with encorafenib plus cetuximab with mFOLFOX6 chemotherapy. Guardant360 CDx enabled rapid ctDNA analysis for treatment selection and resistance monitoring. The study supports the importance of early, comprehensive genomic profiling to improve outcomes in mCRC. Colorectal cancer remains the second-leading cause of cancer-related deaths in the U.S., with BRAF V600E mutations present in approximately 8 to 10 percent of mCRC cases.1 The mutation is a molecularly distinct and aggressive subtype of mCRC with poor prognosis and limited treatment options. Early identification of this mutation is critical to guiding patients to more effective, targeted therapies. Guardant360 CDx offers a convenient and accessible method for detecting this actionable biomarker, especially when tissue samples are unavailable or inadequate for testing. This latest FDA approval for Guardant 360 CDx marks the 25th companion diagnostic indication across multiple tumor types and builds on the platform’s increasing clinical utility and broad coverage by Medicare and commercial payers, representing more than 300 million covered lives. About Guardant360® CDx Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling. It detects multiple genomic alterations across all solid tumors and is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer, and now colorectal cancer. For more information, visit Guardant360 CDx. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. 1 Mauri G, et al. Cancers, 2021.

Clinical ResultPhase 3Drug Approval

22 Jan 2026

·firstwordpharma.com

Guardant Health, Pfizer clinch FDA nod for colorectal cancer companion diagnostic

Guardant Health said Thursday that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with Pfizer’s Braftovi (encorafenib) in combination with cetuximab and chemotherapy.The approval is supported by data from the Phase III BREAKWATER trial, which evaluated encorafenib-based regimens in previously untreated patients with BRAF-mutated metastatic colorectal cancer. The study showed that Braftovi and cetuximab plus mFOLFOX6 chemotherapy improved objective response rates as well as progression-free and overall survival compared with standard care, supporting earlier use of anti-EGFR combinations alongside BRAF inhibition in this setting.Guardant360 CDx uses a blood sample to analyse tumour genomic profiles, allowing clinicians to identify BRAF V600E mutations when tumour tissue is unavailable or insufficient. The mutation is present in around 8% to 10% of metastatic colorectal cancers and is associated with poor prognosis and limited treatment options.The colorectal cancer clearance marks the first FDA-approved companion diagnostic indication for Guardant360 CDx in this tumour type. It follows earlier approvals for the liquid biopsy as a companion diagnostic in lung cancer and breast cancer.Guardant said the latest decision brings the total number of FDA-approved companion diagnostic indications for Guardant360 CDx to 25 across multiple tumour types.

Phase 3Clinical ResultDrug Approval

14 Jan 2026

·www.prnewswire.com

AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab

– Collaboration with Blood Cancer United® in its Beat AML® Master Clinical Trial – – AVEO's ficlatuzumab compound to be studied in combination with azacitidine and venetoclax in patients with AML in a Phase 1b/2 clinical trial – – First patient dosed into the Phase 1b/2 clinical trial – BOSTON, Jan. 14, 2026 /PRNewswire/ -- AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and venetoclax in patients that are 60 years of age or older with untreated acute myeloid leukemia (AML) through a Master Clinical Trial Collaboration Agreement with Blood Cancer United®, formerly the Leukemia & Lymphoma Society. As part of this strategic collaboration with Blood Cancer United, a global nonprofit focused on blood cancer patient support, research, and advocacy, Blood Cancer United will be sponsoring the clinical trial as a sub-study in their Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer, which tests multiple therapies in multiple study arms simultaneously. The Phase 1b/2 clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination as a potential treatment for AML. Ficlatuzumab is AVEO's investigational humanized IgG1 monoclonal antibody that is designed to bind to the hepatocyte growth factor (HGF) ligand and prevent it from signaling via the c-Met receptor. Early phase clinical trials evaluating ficlatuzumab in combination with cytarabine in AML reported a favorable safety profile with promising clinical activity, supporting ficlatuzumab for further study in AML patients, particularly in those who are considered unfit for standard intensive first-line therapy. "This is a significant milestone for AVEO and Blood Cancer United, who are both dedicated to improving patient outcomes through novel clinical research," said Michael P. Bailey, President and CEO of AVEO. "We welcome this partnership and are excited to collaborate on this important clinical trial as we continue to expand our efforts to address high unmet medical needs with our novel clinical stage portfolio of therapies." "The Beat AML Master Clinical Trial seeks to change the paradigm for how this deadly cancer is treated, using an innovative precision medicine protocol and implementing strategic partnerships," said Lore Gruenbaum, Ph.D, Chief Scientific Officer of Blood Cancer United. "Our collaboration with AVEO is a key next step for the trial and transforming patient care for adults with AML." About AVEO Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. About LG Chem, Ltd. and LG Chem Life Sciences LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit . About Blood Cancer United® and the Beat AML® Master Clinical Trial Blood Cancer United (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization's mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives. For support and to learn more, visit . The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match patients to the most promising targeted treatment based on their unique genetic mutations. The trial tests multiple therapies in multiple sub-studies simultaneously and has already generated strong results, demonstrating positive survival rates and better quality of life. Over the past decade, Beat AML has grown into a powerful ecosystem of pharma companies, genetic testing experts, data specialists, regulatory agencies, and other industry partners working toward better and safer treatments for patients with AML. For more information, visit . About Ficlatuzumab Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 inhibitory antibody that binds to the HGF ligand with high affinity and specificity. HGF is the natural ligand of c-Met and blocking HGF inhibits signaling through the HGF/c-Met signaling pathway. The U.S. Food and Drug Administration designated as a Fast Track development program the investigation of ficlatuzumab and ERBITUX® (cetuximab) for relapsed/recurrent HNSCC in September 2021, which is currently in a Phase 3 clinical study. Contacts Media: John F. Kouten JFK Communications, Inc. 908-227-4714 [email protected] SOURCE AVEO, an LG Chem company 21% more press release views with Request a Demo

Phase 3Fast Track

100 Deals associated with Cetuximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03455	Cetuximab	L01XC06	DB00002

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
BRAF V600E mutant Colorectal Cancer	China	Merck Europe BV	30 Sep 2025
RAS Wild Type Colorectal Cancer	Australia	Merck Healthcare Pty Ltd.	25 Sep 2007
Head and Neck Neoplasms	United States	Eli Lilly & Co.	01 Mar 2006
Metastatic Colorectal Carcinoma	European Union	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Iceland	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Liechtenstein	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Norway	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	European Union	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Iceland	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Liechtenstein	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Norway	Merck Europe BV	29 Jun 2004
Colorectal Cancer	Switzerland	Merck & Co., Inc.	01 Dec 2003

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma	Phase 3	United States	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	China	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Japan	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Argentina	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Australia	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Brazil	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Finland	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	France	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Germany	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Hong Kong	Merck Sharp & Dohme LLC	16 Jul 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06358430 (ASCO_GI2026)	Phase 1	Colorectal Cancer	14	TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells+cetuximab	qgldiipvbb(usonmmozyy) = ovqtnjxlad bgvxsqvich (uxamxmkqmc ) View more	Positive	08 Jan 2026
NCT06978400 (ASCO_GI2026)	Phase 2	BRAF V600E mutant Colorectal Cancer First line BRAF V600E mutation \| MSS	64	FOLFOX with dabrafenib and cetuximab/panitumumab (MSS and BRAF V600E mutation + metastatic colorectal cancer)	rzaohhpgzr(kstrursbzd) = rtzijzgaml ezxbtmexzy (aunwyrinbj )	Positive	08 Jan 2026
NCT04224415 (ASCO_GI2026)	Phase 2	RAS/BRAF Wild Type Colorectal Cancer RAS \| BRAF	36	Cetuximab plus irinotecan	xeyvjhauca(edjfmjqkij) = bgpzikqoll daaekuawcc (pjbwudlgyl, 5.6 - 30.6) View more	Positive	08 Jan 2026
NCT06321081 (ASCO_GI2026)	Phase 2	RAS/BRAF wild-type \| MSS	20	Irinotecan + Cetuximab + Envafolimab	cznqhjozsz(ahifbiwpcg) = lkapgyrwoe zzdacxybpd (omibrpuoys ) View more	Positive	08 Jan 2026
NCT04587128 (ASCO_GI2026)	Phase 2	Metastatic Colorectal Carcinoma First line RAS/RAF wildtype	21	Panitumumab or Cetuximab	yzbeyrvtjd(pqdvnqkazh) = qrrlefiaqp mhurozcgra (tdzgvplxaj ) View more	Positive	08 Jan 2026
NCT04349267 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm	44	BMS-986315 (Part 1A BMS-986315-80 mg)	ddoztjdbiu = kokgpkvvuo qorsnzbzoh (arsyigrkkl, lwujquqhjo - dpxolityuc) View more	-	17 Dec 2025
NCT04349267 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm	44	BMS-986315 (Part 1A BMS-986315-200 mg)	ddoztjdbiu = isjhqmmcld qorsnzbzoh (arsyigrkkl, bxkwfmjiwv - qemafvxyuw) View more	-	17 Dec 2025
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer First line	969	Panitumumab	ixawxnydmb(mbudkkelvg) = itpfiklfpb rvowbkmwzt (zxhpqplqic, 23.68 - 38.12) View more	Positive	05 Dec 2025
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer First line	969	Cetuximab	ixawxnydmb(mbudkkelvg) = kvclvyuzrw rvowbkmwzt (zxhpqplqic, 25.17 - 31.36) View more	Positive	05 Dec 2025
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer	101	Cetuximab + standard therapy	xhssworcca(lllxehgpul) = vfrtshpkiu lfzbniynta (eodlkfshxc ) View more	Positive	05 Dec 2025
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer	101	Cetuximab + standard therapy (left-sided mCRC)	xhssworcca(lllxehgpul) = pvecoxogde lfzbniynta (eodlkfshxc ) View more	Positive	05 Dec 2025
CeRWIN (ESMO_ASIA2025)	Not Applicable	Squamous Cell Carcinoma of Head and Neck EGFR	136	Biosimilar cetuximab (alone or with chemotherapy/radiotherapy)	otqjlatgwl(vxctyaqast) = maxpfrhctb nruuyapxcd (gzntqjmbic ) View more	Positive	05 Dec 2025
NCT04607421 (BREAKWATER, ESMO_ASIA2025)	Phase 3	BRAF V600E mutant Colorectal Cancer First line BRAF V600E-mutant	225	Encorafenib + cetuximab	iskyzrjumc(ztqxnvhqdc) = tunbfdpjkq hkfkgzgaxi (pxjtlhljaj, 4.1 - 16.1) View more	Positive	05 Dec 2025
NCT04607421 (BREAKWATER, ESMO_ASIA2025)	Phase 3		225	Encorafenib + cetuximab + mFOLFOX6	iskyzrjumc(ztqxnvhqdc) = ravbikgozh hkfkgzgaxi (pxjtlhljaj, 13.9 - NE) View more	Positive	05 Dec 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Cetuximab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation